11 results about "Procaine" patented technology

This invention discloses a rapid mass spectrometry method and kit for the simultaneous detection of multiple components in body fluids, belonging to the field of biological detection and identification technology. It can rapidly detect trace compounds such as drugs and biomarkers in complex biological samples. This kit mainly utilizes loaded functional materials to achieve extraction and enrichment of target analytes and is equipped with a quick connector for coupling with a detector to achieve rapid detection. Compared with traditional methods, the significant advantages of the method established by this kit are that it does not require complex sample pretreatment, allows for micro-quantitative sampling, requires small sample volumes, facilitates convenient storage of biological samples, is easy to operate, does not require specialized technical personnel, and enables rapid on-site detection when coupled with portable mass spectrometry. This kit has been successfully used for the detection of quinine, procainamide hydrochloride, atenolol, and nortriptyline in complex samples such as blood and serum, and has significant clinical and economic value.

The invention relates to an activated form of procaine, and the use of the activated procaine, or salts or solvates thereof, to label amine-containing compounds, such as N-glycans, amine-containing amino acids, amine-containing peptides, amine-containing proteins, or other amine-containing compounds in a sample. Use of activated procaine as a label allows for sensitive detection of compounds labeled with it by both fluorescence and mass spectrometry.

The invention relates to the technical field of pharmaceutical co-crystals, and particularly discloses a benzocain-3, 5-dihydroxybenzoic acid co-crystal as well as a preparation method and application of the benzocain-3, 5-dihydroxybenzoic acid co-crystal. The benzocain-3, 5-dihydroxy benzoic acid eutectic crystal provided by the invention comprises benzocaine and 3, 5-dihydroxy benzoic acid, and the molar ratio of the benzocaine to the 3, 5-dihydroxy benzoic acid is 1: (0.8-1.2). According to the benzocain-3, 5-dihydroxybenzoic acid eutectic crystal prepared by the invention, the equilibrium solubility, antibacterial property and stability of benzocaine can be effectively improved; the preparation method of the benzocain-3, 5-dihydroxy benzoic acid eutectic crystal provided by the invention is simple in process, easy to control the crystallization process and good in reproducibility, and has relatively good economical efficiency and industrial production value.

The invention relates to the technical field of catalytic hydrogenation, in particular to a catalyst and application thereof in preparation of procaine through hydrogenation, a high-molecular compound is introduced to the surface of a zirconium oxide carrier for pretreatment, a high-density oxygen defect structure is formed through roasting induction, and the interaction between active metal platinum and a carrier ZrO2 is remarkably enhanced; according to the preparation method, double assistant metals are adopted for synergistic modification, so that breakage of side reaction ester bonds can be effectively inhibited, the reaction selectivity and the target product yield are improved, alcohol byproducts and hydroxylamine byproducts are reduced, sharing of sodium hyaluronate and assistant metals is introduced, uniform distribution of the assistant metals on the surface of a carrier is promoted, and the agglomeration phenomenon is avoided; meanwhile, high dispersity and stability of the metal particles are guaranteed, so that the catalyst is endowed with excellent catalytic activity, selectivity and regeneration performance, the regenerated and activated catalyst still can keep good performance, and the catalyst is particularly suitable for hydrogenation of nitro compounds with ester groups.

The present invention relates to a contour injection composition, and more specifically, is characterized by an injection composition comprising a solvent, aminophylline, procaine, epinephrine, and hyaluronidase, the injection composition comprising, on the basis of the entire composition, 500 to 700 IU units hyaluronidase, and 0.05 to 0.15% (w / v) aminophylline, 0.01 to 0.03% (w / v) procaine, 0.001 to 0.006% (w / v) epinephrine, and the remainder the solvent, wherein the solvent is half saline and distilled water. According to the present invention, the injection composition has excellent fat decomposition and fat destruction effects and cellulite reduction effect, as well as effect in improving a circulation function, thereby reducing subcutaneous fat in a desired area, and having the advantages not only of improving body and facial lines by improving elasticity, but also not causing side effects such as redness, itchiness, swelling, skin depression, and skin sagging.

The invention provides a procaine amine dimer H2S removal agent as well as a preparation method and application thereof, and the procaine amine dimer H2S removal agent provided by the invention does not cause the scaling problem caused by the increase of the pH value of a system; after the procaine amine dimer H2S removal agent reacts with H2S, the product is soluble or dispersible, so that the problem of pipe blockage caused by insolubility of the desulfurization product of the traditional triazine desulfurization agent is solved, and the desulfurization agent is the biggest innovation; molecules of the dimer H2S removal agent contain a plurality of desulfurization groups, two tertiary amine groups can quickly absorb hydrogen sulfide to achieve the purpose of sulfur fixation, and meanwhile, the dimer H2S removal agent has two C = N bonds which can react with H2S, so that the desulfurization effect is outstanding; according to the dimer H2S removal agent, a desulfurization product cannot be decomposed again to release H2S gas, and desulfurization is thorough; the removing agent is applied to natural gas containing hydrogen sulfide and gas-phase and liquid-phase environments of oil fields, can well remove hydrogen sulfide in the environments, and improves the safety of the environments.

The invention belongs to the technical field of anesthesia dressings, and discloses a pharmaceutical composition for local anesthesia and a preparation method thereof. The pharmaceutical composition for local anesthesia is prepared from the following components: 10 to 20 parts of procaine, 0.9 to 1.5 parts of bergenin, 3 to 5 parts of a stabilizer, 5 to 10 parts of a surfactant, 1 to 3 parts of sodium carboxymethyl cellulose and 70 to 80 parts of normal saline. When the pharmaceutical composition for local anesthesia is applied to the skin, the anesthetic effect of the drug procaine can be remarkably enhanced, the local anesthesia duration can be prolonged, the clinical administration frequency can be reduced, and the stability of the drug procaine can be improved. The pharmaceutical composition for local anesthesia is safe and non-irritant to skin, and has a good application prospect.

The application discloses a compound procaine penicillin suspension injection, which contains the following raw and auxiliary materials in 100 mL of the suspension injection: 5-30 g of procaine penicillin, 5-30 g of dihydrostreptomycin sulfate, 0.5-1.5 g of non-ionic surfactant, and the balance of injection solvent; the non-ionic surfactant contains a diaryl secondary amine structure, a cyclohexane structure, an ester group and a hydroxyl group, has good compatibility with the procaine penicillin, the dihydrostreptomycin sulfate and the injection solvent, can not only reduce the interfacial tension of each component in the mixture system, increase the dispersibility and stability of the mixture system, but also improve the sedimentation volume ratio and the needle passability of the suspension injection; and the application further discloses a preparation method of the suspension injection. The compound procaine penicillin suspension injection provided by the application is safe and effective, has a high sedimentation volume ratio, excellent stability, dispersibility and needle passability.

The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and / or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.

A sterile ophthalmic gel of chloroprocaine having improved functionality, pharmacokinetics, and stability, particularly with respect to clarity, and methods of making and using the same.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a method for preparing chloroprocaine hydrochloride and its intermediates, and their applications. The invention uses 2-chloro-4-nitrobenzoic acid and N,N-diethylethanolamine as starting materials, and prepares nitrochlorocaine via sulfuric acid-catalyzed esterification. Nitrochlorocaine is then reduced with thiourea dioxide to obtain crude chloroprocaine. The crude chloroprocaine is then salted in hydrochloric acid and ethanol, crystallized, and dried to obtain the final product, chloroprocaine hydrochloride. This method features low cost, high product quality, high yield, simple process, high production capacity, environmental friendliness, and suitability for industrial production, thus possessing significant industrialization value.